 |
|
Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
Tom Walsh, PhD;
Silvia Casadei, PhD;
Kathryn Hale Coats, BS;
Elizabeth Swisher, MD;
Sunday M. Stray, BS;
Jake Higgins, BS;
Kevin C. Roach, BS;
Jessica Mandell, MS, CGC;
Ming K. Lee, PhD;
Sona Ciernikova, PhD;
Lenka Foretova, MD, PhD;
Pavel Soucek, PhD;
Mary-Claire King, PhD
JAMA. 2006;295:1379-1388.
Context Genetic testing for inherited mutations in BRCA1 and BRCA2 has become integral to the care of women with a severe family history of breast or ovarian cancer, but an unknown number of patients receive negative (ie, wild-type) results when they actually carry a pathogenic BRCA1 or BRCA2 mutation. Furthermore, other breast cancer genes generally are not evaluated.
Objective To determine the frequency and types of undetected cancer-predisposing mutations in BRCA1, BRCA2, CHEK2, TP53, and PTEN among patients with breast cancer from high-risk families with negative (wild-type) genetic test results for BRCA1 and BRCA2.
Design, Setting, and Participants Between 2002-2005, probands from 300 US families with 4 or more cases of breast or ovarian cancer but with negative (wild-type) commercial genetic test results for BRCA1 and BRCA2 were screened by multiple DNA-based and RNA-based methods to detect genomic rearrangements in BRCA1 and BRCA2 and germline mutations of all classes in CHEK2, TP53, and PTEN.
Main Outcome Measures Previously undetected germline mutations in BRCA1, BRCA2, CHEK2, TP53, and PTEN that predispose to breast cancer; frequencies of these mutations among families with negative genetic test results.
Results Of the 300 probands, 52 (17%) carried previously undetected mutations, including 35 (12%) with genomic rearrangements of BRCA1 or BRCA2, 14 (5%) with CHEK2 mutations, and 3 (1%) with TP53 mutations. At BRCA1 and BRCA2, 22 different genomic rearrangements were found, of sizes less than 1 kb to greater than 170 kb; of these, 14 were not previously described and all were individually rare. At CHEK2, a novel 5.6-kb genomic deletion was discovered in 2 families of Czechoslovakian ancestry. This deletion was found in 8 of 631 (1.3%) patients with breast cancer and in none of 367 healthy controls in the Czech and Slovak Republics. For all rearrangements, exact genomic breakpoints were determined and diagnostic primers validated. The 3 families with TP53 mutations included cases of childhood sarcoma or brain tumors in addition to multiple cases of breast cancer.
Conclusions The mutational spectra of BRCA1 and BRCA2 include many high-penetrance, individually rare genomic rearrangements. Among patients with breast cancer and severe family histories of cancer who test negative (wild type) for BRCA1 and BRCA2, approximately 12% can be expected to carry a large genomic deletion or duplication in one of these genes, and approximately 5% can be expected to carry a mutation in CHEK2 or TP53. Effective methods for identifying these mutations should be made available to women at high risk.
Author Affiliations: Departments of Medicine and Genome Sciences (Drs Walsh, Casadei, Lee, and King and Mss Coats, Stray, and Mandell and Mssrs Higgins and Roach) and Obstetrics and Gynecology, University of Washington, Seattle (Dr Swisher); Department of Medical Oncology, Morgagni-Pierantoni Hospital, Forlì, Italy (Dr Casadei); Department of Cancer Genetics, Cancer Research Institute of Slovak Academy of Sciences, Bratislava, Slovak Republic (Dr Ciernikova); Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic (Dr Foretova); and Center of Occupational Diseases, National Institute of Public Health, Prague, Czech Republic (Dr Soucek).
RELATED LETTERS
Mutations in Families at High Risk for Breast Cancer
Peter Cheung
JAMA. 2006;296(17):2091.
EXTRACT
| FULL TEXT
Mutations in Families at High Risk for Breast Cancer—Reply
Tom Walsh, Silvia Casadei, Elizabeth Swisher, Sunday M. Stray, Jake Higgins, Kevin C. Roach, Ming K. Lee, and Mary-Claire King
JAMA. 2006;296(17):2091-2092.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical Classification of BRCA1 DNA Missense Variants: H1686Q Is a Novel Pathogenic Mutation Occurring in the Ontogenetically Invariant THV Motif of the N-Terminal BRCT Domain
Giannini et al.
JCO 2008;26:4212-4214.
FULL TEXT
Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes: A Paper from the 2007 William Beaumont Hospital Symposium on Molecular Pathology
Allain
J. Mol. Diagn. 2008;10:383-395.
ABSTRACT
| FULL TEXT
The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families
Palma et al.
Cancer Res. 2008;68:7006-7014.
ABSTRACT
| FULL TEXT
The Role of the BRCA2 Gene in Susceptibility to Prostate Cancer Revisited
Ostrander and Udler
Cancer Epidemiol. Biomarkers Prev. 2008;17:1843-1848.
ABSTRACT
| FULL TEXT
CHEK2 1100delC Is a Susceptibility Allele for HNPCC-Related Colorectal Cancer
Wasielewski et al.
Clin. Cancer Res. 2008;14:4989-4994.
ABSTRACT
| FULL TEXT
Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional Consequences
Fox et al.
J. Biol. Chem. 2008;283:21179-21186.
ABSTRACT
| FULL TEXT
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers
Cybulski et al.
Carcinogenesis 2008;29:762-765.
ABSTRACT
| FULL TEXT
The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations
Fatouros et al.
Ann. Surg. Oncol. 2008;15:21-33.
ABSTRACT
| FULL TEXT
Genetic Testing in Diverse Populations: Are Researchers Doing Enough to Get Out the Correct Message?
Huo and Olopade
JAMA 2007;298:2910-2911.
FULL TEXT
Update in Oncology
Schnipper
ANN INTERN MED 2007;147:775-782.
FULL TEXT
BRCA1 and BRCA2 Mutations in an Asian Clinic-based Population Detected Using a Comprehensive Strategy
Ang et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2276-2284.
ABSTRACT
| FULL TEXT
Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients
Vaz et al.
J. Histochem. Cytochem. 2007;55:1105-1113.
ABSTRACT
| FULL TEXT
Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-Risk Hispanic Families
Weitzel et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:1615-1620.
ABSTRACT
| FULL TEXT
CHEK2 Mutation and Hereditary Breast Cancer
Bogdanova et al.
JCO 2007;25:e26-e26.
FULL TEXT
In Reply
Parmigiani and Berry
JCO 2007;25:2634-2635.
FULL TEXT
Clinical Implications of Founder and Recurrent CDH1 Mutations in Hereditary Diffuse Gastric Cancer
Kangelaris and Gruber
JAMA 2007;297:2410-2411.
FULL TEXT
Schizophrenia: a common disease caused by multiple rare alleles
McClellan et al.
Br. J. Psychiatry 2007;190:194-199.
ABSTRACT
| FULL TEXT
Perspective on Genes and Mutations Causing Retinitis Pigmentosa
Daiger et al.
Arch Ophthalmol 2007;125:151-158.
ABSTRACT
| FULL TEXT
CHEK2 Mutation and Hereditary Breast Cancer
Narod and Lynch
JCO 2007;25:6-7.
FULL TEXT
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2
Alter et al.
J. Med. Genet. 2007;44:1-9.
ABSTRACT
| FULL TEXT
Mutations in families at high risk for breast cancer.
Cheung
JAMA 2006;296:2091-2091.
FULL TEXT
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer
Cybulski et al.
J. Med. Genet. 2006;43:863-866.
ABSTRACT
| FULL TEXT
Genomic Rearrangements of the PRPF31 Gene Account for 2.5% of Autosomal Dominant Retinitis Pigmentosa.
Sullivan et al.
IOVS 2006;47:4579-4588.
ABSTRACT
| FULL TEXT
Negative BRCA1 and BRCA2 Screen Is Not Reassuring
JWatch Women's Health 2006;2006:7-7.
FULL TEXT
What's new in the other general journals
Tonks
BMJ 2006;332:842-843.
FULL TEXT
Women's Health--Advances in Knowledge and Understanding
DeAngelis and Glass
JAMA 2006;295:1448-1450.
FULL TEXT
|
